PHAR - Pharming Group outlines 2025 revenue guidance of $315M to $335M driven by RUCONEST and Joenja growth
2025-03-13 19:45:04 ET
More on Pharming, Pharming Group N.V., etc.
- Pharming Group N.V. (PHAR) Q4 2024 Earnings Call Transcript
- Pharming Group appoints former Novartis USA President Fabrice Chouraqui as New CEO
- Pharming Group offers to buy Sweden's Abliva for SEK 0.45/shr
- Seeking Alpha’s Quant Rating on Pharming
- Historical earnings data for Pharming